What is the clinical significance
V2R is the unique validated therapeutic target for treating the
autosomal dominant polycystic kidney disease, an unmet therapeutic need.
MQ1 is a promising therapeutic agent against this disease. The MQ1/V2R
interaction described here will help to improve MQ1 efficiency against
this disease.